Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

BRAF proteins and MEK proteins help control the growth and spread of healthy cells. The BRAF mutation occurs in the gene. It causes the creation of defective BRAF proteins. When this happens ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

A research team led by Sheri Holmen, Ph.D., investigator at Huntsman Cancer Institute and professor in the Department of Surgery at the University of Utah (the U), is testing a new combination drug ...

The original agreement last year focused on melanoma patients who are receiving BRAF/MEK combination therapies – specifically Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib ...

One of the standard treatment options for melanoma over the last ten years has been to simultaneously target both BRAF mutations and MEK. These two genes are part of the MAPK signalling pathway ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

Mutations in the RAS-RAF-MEK-ERK pathway that drive many forms of human malignancies. In particular, the serine/threonine kinase BRAF is mutated in ~8% of all cancers. Targeted inhibitors have been ...

The combination of Hsp90 inhibitors with RAF or MEK inhibitors may achieve a better pathway inhibition in RAS and/or BRAF mutant tumors. This work will contribute significantly toward better patient ...